Oneness Biotech Co., Ltd. (TPEX:4743)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
57.50
+0.10 (0.17%)
Jun 6, 2025, 9:00 AM CST
-60.28%
Market Cap 27.45B
Revenue (ttm) 117.33M
Net Income (ttm) -1.23B
Shares Out 478.26M
EPS (ttm) -2.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,000
Average Volume 1,756,089
Open 57.60
Previous Close 57.40
Day's Range 57.50 - 57.60
52-Week Range 51.40 - 184.00
Beta 0.58
RSI 40.20
Earnings Date May 13, 2025

About Oneness Biotech

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products primarily in Taiwan. It offers Fespixon cream for diabetic foot ulcers. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the tre... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 43
Stock Exchange Taipei Exchange
Ticker Symbol 4743
Full Company Profile

Financial Performance

In 2024, Oneness Biotech's revenue was 117.93 million, an increase of 35.89% compared to the previous year's 86.78 million. Losses were -1.17 billion, -11.25% less than in 2023.

Financial Statements

News

There is no news available yet.